Case Studies: How Patient Input Is Changing R&D

US FDA's patient-focused drug development meeting on sickle cell disease inspired Global Blood Therapeutics to develop a new patient-reported outcomes instrument, while an externally led meeting on amyloidosis confirmed for Alnylam that its pivotal trial was studying clinically meaningful secondary endpoints.